ArticlePediatric research2026
Community-based monitoring of neonatal jaundice using the point-of-care Bilistick® System 2.0.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeonatal jaundice often peaks after discharge, creating the need for reliable post-discharge monitoring. This study evaluated the feasibility and safety of a hospital-to-community pathway using the Bilistick® System 2.0 within routine Community Health Family Services (CHFS).
methodsThis retrospective observational study was conducted within a Local Health Authority in northeastern Italy. Newborns eligible for out-of-hospital bilirubin testing according to a Diagnostic-Therapeutic Assistance Pathway (DTAP) were referred either to CHFS or to hospital follow-up based on bilirubin risk profile, clinical factors, and organizational considerations.
resultsOf 397 eligible newborns meeting inclusion criteria, 244 were included. Of these, 108 (44.3%) were referred to CHFS, 135 (55.3%) to hospital follow-up, and 1 was lost to follow-up. Among newborns referred to CHFS, 97 (89.8%) completed monitoring without hospital referral. Eleven were referred to the hospital, of whom 7 received phototherapy. Among newborns referred directly to the hospital, 6 (4.4%) required phototherapy. No sampling-related adverse events, missed phototherapy, exchange transfusions, or cases of kernicterus were recorded.
conclusionCommunity-based bilirubin monitoring using the Bilistick® System 2.0 appears feasible and safe for selected low-risk newborns within a structured hospital-to-community pathway. IMPACT: To our knowledge, this is the first real-world evaluation of a structured hospital-to-community pathway integrating point-of-care bilirubin testing into routine community care within UNICEF's Baby-Friendly Initiative framework. Among selected newborns referred to community services, 89.8% completed bilirubin monitoring without hospital referral. Community midwives identified infants requiring escalation of care; no missed phototherapy, exchange transfusion, or kernicterus occurred. The model may reduce unnecessary hospital reassessment and disruption to the mother-infant dyad; local administrative estimates indicate a direct cost difference of €32.30 per bilirubin reassessment.
Identifiers
42855462What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.